Trials / Completed
CompletedNCT04664218
Are You in a Poor Country; HIPEC is Still in Reach
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 50 (actual)
- Sponsor
- Zagazig University · Other Government
- Sex
- All
- Age
- 20 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
Peritoneal carcinomatosis (PC) is a well-known sequel of multiple abdominal malignancies either arising from the gastro-intestinal tract or of gynaecologic origin. On occurrence, PC is mostly considered as a very bad prognostic sign hence it affects the overall survival with very poor response to systemic chemotherapy. On introduction of the new concept of combined optimal cytoreduction (CRS) followed by hyperthermic intraperitoneal chemotherapy (HIPEC), promising prognosis began to be shown. A major obstacle which may face application of HIPEC manoeuvre is the cost either of the machine or the disposable kit used in handling the chemotherapy, heating it and delivering it to the patient, hence we established our machine design with its disposable kits making it available for use in poor places.
Detailed description
As aforementioned the use of HIPEC technique offered a promising results in dealing with peritoneal carcinomatosis the high costs seems to be a considerable obstacle in some poor places so we inented a machine with considerably lower costs both in the machine composition and its disposable kit used for every patient we used it for six years in a trial to find any shortage, obstacles or any technical, therapeutic or financial drawbacks compared to the published data of the standard machines
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | HIPEC device | To report the affordability on using the HIPEC machine of our design compared to the standard ones in poor places. |
Timeline
- Start date
- 2014-01-01
- Primary completion
- 2020-01-01
- Completion
- 2020-04-01
- First posted
- 2020-12-11
- Last updated
- 2020-12-11
Source: ClinicalTrials.gov record NCT04664218. Inclusion in this directory is not an endorsement.